ERBB3: A Potential Drug Target and Biomarker for Cancer (G2065)

Target Name: ERBB3

NCBI ID: G2065

ERBB3

ERBB3: A Potential Drug Target and Biomarker for Cancer

ERBB3 (V-erb-b2 erythroblastic leukemia viral oncogene homolog 3) is a gene that encodes a protein known as EBP506, which is a transcription factor that plays a crucial role in the development and progression of various types of cancer. One of the most promising aspects of EBP506 is its potential as a drug target or biomarker for the treatment of cancer.

The ERBB3 gene was identified as a potential drug target by researchers using various techniques, including gene expression analysis and bioinformatics analysis. These studies revealed that EBP506 was highly expressed in various types of cancer, including leukemia, lung cancer, and breast cancer. Additionally, the researchers found that inhibiting the activity of EBP506 using small interfering RNA (siRNA) or CRISPR/Cas9 genome editing technology did not significantly affect the growth or survival of cancer cells.

The potential mechanism of action of EBP506 as a drug target is its role in the regulation of cell growth and proliferation. EBP506 is a transcription factor that regulates the expression of genes involved in cell growth and differentiation, as well as cell survival and apoptosis. This suggests that targeting EBP506 with drugs or other therapeutic agents may be effective in inhibiting the uncontrolled growth and proliferation of cancer cells.

Another potential mechanism of action for EBP506 as a drug target is its role in the development of cancer stem cells. Cancer stem cells are a subtype of cell that have the ability to self-renew and differentiate into any type of cell in the body, and are often responsible for the development and progression of cancer. EBP506 has been shown to play a role in the self-renewal and survival of cancer stem cells. Therefore, targeting EBP506 with drugs or other therapeutic agents that can inhibit its activity may be effective in reducing the number of cancer stem cells and potentially leading to a more effective treatment of cancer.

In addition to its potential as a drug target, EBP506 also has potential as a biomarker for the diagnosis and prognosis of various types of cancer. The researchers have used EBP506 as a marker for the treatment of various types of cancer, including leukemia, lung cancer, and breast cancer. By measuring the level of EBP506 in cancer cells, researchers have been able to monitor the effectiveness of different treatments and determine the potential for future treatments.

The identification of EBP506 as a potential drug target and biomarker for cancer has important implications for the development of new treatments for these deadly diseases. Further research is needed to fully understand the role of EBP506 in the development and progression of cancer, as well as its potential as a drug target or biomarker. However, the potential of EBP506 as a drug target and biomarker for cancer makes it an important area of research that should be further explored.

Protein Name: Erb-b2 Receptor Tyrosine Kinase 3

Functions: Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778). May also be activated by CSPG5 (PubMed:15358134). Involved in the regulation of myeloid cell differentiation (PubMed:27416908)

The "ERBB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERBB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets